Pfizer Inc. (NYSE: PFE), and AstraZeneca plc (NASDAQ: AZN) may have faded from the spotlight since the peak of the COVID-19 ...

Chronic ocular pain market is poised for significant growth, fueled by increasing awareness, innovative treatments, and a ...

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% ...

At Lilly, Paul helped develop the company’s mental health blockbusters, Zyprexa and Cymbalta, and helped oversee development of muscarinic cholinergic receptor agonist xanomeline, where its ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly lost the momentum it had during the first half of the year. However, the company still has plenty of long-term growth drivers. The pharmaceutical giant's prospects justify its current ...

After hours: 22 November at 19:59 GMT-5 ...